ErbB-4 s80 Intracellular Domain Abrogates ETO2-dependent Transcriptional Repression
Open accessThe DOI matches its Crossref record.
Abstract
ErbB-4 is cleaved by alpha- and gamma-secretases to release a soluble 80-kDa intracellular domain, termed s80, which translocates to the nucleus. s80 is present in the nucleus of normal and cancerous mammary cells and is predicted to have a role in cell differentiation. To further investigate the mechanism by which s80 may mediate differentiation, we tested whether s80 regulates Eto2, a transcriptional corepressor that is involved in erythrocyte differentiation and is also implicated in human breast cancer. Here we show that ligand binding to ErbB-4 causes s80 translocation to the nucleus, where it colocalizes and interacts with Eto2. Expression of s80 blocks Eto2-mediated transcriptional repression of a heterologous promoter. This effect on Eto2 does not require s80 kinase activity and is mediated by the carboxyl-terminal region of s80. Although other cell surface receptors regulate transcription by activating signal transduction cascades, these data present a novel mechanism of corepressor regulation and suggest a role for Eto2 in ErbB-4-dependent differentiation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Neuregulin 1 in neural development, synaptic plasticity and schizophrenia
Mei, L., & Xiong, W.-C. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2392 · Cited by 1,030
The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer
Hsu, J. L., & Hung, M.-C. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9649-6 · Cited by 445
Wang, Z. (2017) · Methods in Molecular Biology · doi:10.1007/978-1-4939-7219-7_1 · Cited by 430
The EGF receptor family: spearheading a merger of signaling and therapeutics
Bublil, E. M., & Yarden, Y. (2007) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2007.02.008 · Cited by 397
ErbB receptors: new insights on mechanisms and biology
LINGGI, B., & CARPENTER, G. (2006) · Trends in Cell Biology · doi:10.1016/j.tcb.2006.10.008 · Cited by 377
Self-citationExpression and Function of the Epidermal Growth Factor Receptor in Physiology and Disease
Chen, J., Zeng, F., Forrester, S. J., Eguchi, S., Zhang, M.-Z., & Harris, R. C. (2016) · Physiological Reviews · doi:10.1152/physrev.00030.2015 · Cited by 327
Nuclear trafficking of the epidermal growth factor receptor family membrane proteins
Wang, Y.-N., Yamaguchi, H., Hsu, J.-M., & Hung, M.-C. (2010) · Oncogene · doi:10.1038/onc.2010.157 · Cited by 233
“Nuclear ErbB-4 intracellular domain has also been shown to reduce the transcriptional repression mediated by Eto-2, a tumor suppressor candidate in breast cancer (Linggi and Carpenter, 2006).”
All EGF(ErbB) receptors have preformed homo- and heterodimeric structures in living cells
Tao, R.-H., & Maruyama, I. N. (2008) · Journal of Cell Science · doi:10.1242/jcs.033399 · Cited by 206
“The four ErbB family members recognize at least 11 different but structurally related growth factors including epidermal growth factor (EGF), transforming growth factor α (TGF-α) and neuregulins (NRGs) (Citri and Yarden, 2006; Linggi and Carpenter, 2006a).”
BackgroundInfluentialNuclear Signaling by Receptor Tyrosine Kinases: The First Robin of Spring
Schlessinger, J., & Lemmon, M. A. (2006) · Cell · doi:10.1016/j.cell.2006.09.013 · Cited by 98
The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein
Lucas, L. M., Dwivedi, V., Senfeld, J. I., Cullum, R. L., Mill, C. P., Piazza, J. T., Bryant, I. N., Cook, L. J., Miller, S. T., Lott, J. H., et al. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000381 · Cited by 70
“Additional transcriptional regulatory proteins whose functions are in some cases dependent on the 4ICD include the Yes-associated protein 1 (YAP1) (Komuro et al., 2003; Omerovic et al., 2004; Aqeilan et al., 2005; Citri and Yarden, 2006; Naresh et al., 2006; Blobel et al., 2009; Veikkolainen et al., 2011; Wang, 2017),…”
Background
Metadata
- Authors
- Linggi, B., & Carpenter, G.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2006-09
- Volume
- 281
- Issue
- 35
- Pages
- 25373-25380
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2090433709
- Cited by
- 64
- References
- 0
- FWCI
- 3.57
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.